Medicus Pharma Stock Debt To Equity
| MDCX Stock | 3.95 0.25 6.76% |
Medicus Pharma fundamentals help investors to digest information that contributes to Medicus Pharma's financial success or failures. It also enables traders to predict the movement of Medicus Stock. The fundamental analysis module provides a way to measure Medicus Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medicus Pharma stock.
Medicus |
Medicus Pharma Company Debt To Equity Analysis
Medicus Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Medicus Pharma has a Debt To Equity of 0.0%. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Debt To Equity (which currently averages 0.0) industry. This indicator is about the same for all Canada stocks average (which is currently at 0.0).
Did you try this?
Run CEOs Directory Now
CEOs DirectoryScreen CEOs from public companies around the world |
| All Next | Launch Module |
Medicus Fundamentals
| Current Valuation | 39.65 M | |||
| Shares Outstanding | 11.82 M | |||
| Number Of Shares Shorted | 900 | |||
| Price To Book | 9.45 X | |||
| Net Income | (6.78 M) | |||
| Total Debt | 1.09 M | |||
| Cash Flow From Operations | (4.16 M) | |||
| Short Ratio | 0.96 X | |||
| Earnings Per Share | (1.25) X | |||
| Target Price | 5.61 | |||
| Market Capitalization | 46.68 M | |||
| Total Asset | 1.89 M | |||
| Retained Earnings | (19.18 M) | |||
| Working Capital | 805.8 K | |||
| Net Asset | 1.89 M |
About Medicus Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medicus Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicus Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicus Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medicus Stock Analysis
When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.